A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Latest Information Update: 23 Dec 2021
Price :
$35 *
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary) ; Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 25 Sep 2020 Primary endpoint has been met. (Area under the curve (AUC)0-4h mixed meal tolerance test(MMTT) stimulated C-peptide concentration-time curve)
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association